NASDAQ · WGSWW
Healthcare · Medical - Healthcare Information Services
$0.00
Up+$0.00 (+0.00%)
Updated Sep 14, 2026, 1:47 AM
SID Score
2.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
WGSWW does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning WGSWW.
WGSWW research
Company profile and research snapshot.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Yahoo · Feb 25, 2026
GAITHERSBURG, Md., February 25, 2026--GeneDx (Nasdaq: WGS) announced that company management will participate in the upcoming TD Cowen and Barclays healthcare investor conferences.
Yahoo · Feb 25, 2026
The fair value price target for GeneDx Holdings sits at US$170.0, with the latest update keeping this headline target unchanged. Bullish analysts link this steady target to the Wells Fargo upgrade and the launch of GenomeDx Prenatal, while more cautious views question how quickly the new test can support the story embedded in current models. As you read on, you will see how these differing views shape the evolving analyst narrative and what to watch as new information comes through. Analyst...
Yahoo · Feb 23, 2026
Katherine Stueland: We reported quarterly revenues of $121,000,000, bringing full-year revenues to $428,000,000, underpinned by 54% exome and genome revenue growth. 2026 is going to be a breakout year for GeneDx Holdings Corp. We are operating in an enormous and largely untapped market with a twenty-five year head start.
Yahoo · Feb 23, 2026
GENEDX HOLDINGS (WGS) delivered earnings and revenue surprises of +27.27% and +1.50%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning WGSWW.
No results
No recent SID articles mention WGSWW.
